This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Why Alkermes (ALKS) Might Surprise This Earnings Season
by Zacks Equity Research
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Down 8.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes beats earnings and sales estimates in the fourth quarter of 2019.
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
by Zacks Equity Research
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day.
Alkermes (ALKS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session.
LGND vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
Alnylam Stock Up More Than 61% YTD on Pipeline Progress
by Zacks Equity Research
Shares of Alnylam (ALNY) rise on significant pipeline progress.
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
by Zacks Equity Research
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
New Strong Buy Stocks for December 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Seattle Genetics Submits NDA to FDA for Tucatinib Combo
by Zacks Equity Research
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Alkermes (ALKS) closed the most recent trading day at $20.92, moving -0.66% from the previous trading session.
All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy
by Zacks Equity Research
Alkermes (ALKS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
by Zacks Equity Research
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
New Strong Buy Stocks for December 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
5 Losing Stocks From 2019 to Rebound Next Year
by Maharathi Basu
The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis
by Zacks Equity Research
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.